Moreno-Càceres Joaquim, Fabregat Isabel
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Physiological Sciences II, University of Barcelona, Spain.
Hepat Oncol. 2015 Oct;2(4):381-397. doi: 10.2217/hep.15.27. Epub 2015 Nov 11.
Hepatocellular carcinoma (HCC) is a major health problem. In human hepatocarcinogenesis, the balance between cell death and proliferation is deregulated, tipping the scales for a situation where antiapoptotic signals are overpowering the death-triggering stimuli. HCC cells harbor a wide variety of mutations that alter the regulation of apoptosis and hence the response to chemotherapeutical drugs, making them resistant to the proapoptotic signals. Considering all these modifications found in HCC cells, therapeutic approaches need to be carefully studied in order to specifically target the antiapoptotic signals. This review deals with the recent relevant contributions reporting molecular alterations for HCC that lead to a deregulation of apoptosis, as well as the challenge of death-inducing chemotherapeutics in current HCC treatment.
肝细胞癌(HCC)是一个重大的健康问题。在人类肝癌发生过程中,细胞死亡与增殖之间的平衡失调,导致抗凋亡信号压倒触发死亡的刺激因素。HCC细胞存在多种改变细胞凋亡调控的突变,从而影响对化疗药物的反应,使其对促凋亡信号产生抗性。鉴于在HCC细胞中发现的所有这些改变,需要仔细研究治疗方法,以便特异性地靶向抗凋亡信号。本综述探讨了近期有关HCC分子改变导致细胞凋亡失调的相关研究成果,以及当前HCC治疗中诱导死亡的化疗药物所面临的挑战。